Centrum Medyczne Pratia Katowice
- Address
- ul. Dąbrówki 13, 40-081 Katowice, Poland
Immune System and Skin Research
At Centrum Medyczne Pratia Katowice, clinical research in immune system diseases and skin and connective tissue diseases is focused on conditions such as moderate to severe plaque psoriasis. These studies are designed to assess the safety, tolerability, and overall effectiveness of new treatment options for people living with chronic inflammatory skin disease.
- Plaque psoriasis and related immune system processes
- Long-term safety and treatment tolerability of new therapies
- Evaluating whether investigational treatment can better control symptoms and disease burden
This area of research reflects a strong interest in improving care for persistent inflammatory skin conditions through therapies aimed at better disease management and patient comfort.
Sjögren’s Syndrome Studies
Clinical trials at this health care site also include work in immune system phenomena and autoimmune disease, especially Sjögren’s syndrome with moderate-to-severe symptoms. The research is centered on understanding how new therapies may improve patient-reported symptoms and daily well-being in this chronic condition.
- Sjögren’s syndrome and autoimmune disease
- Measuring improvement in patient-reported symptoms
- Testing a potential therapy for symptom relief and disease control
This work highlights efforts to advance treatment options for people affected by immune-mediated disorders, with attention to symptom burden and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 52 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Eli Lilly & Co.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Pratia Katowice
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | May 2023 | Feb 2024 |
IMP list
lock Showing 1 of 52 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Botulinum Toxin Type A - Haemagglutinin Complex | 2 | Unknown | 2024-03-18 | 2024-03-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.